Legault Pierre 4

What Happened
Pierre Legault, a director of Syndax Pharmaceuticals (SNDX), was granted 24,000 restricted stock units (RSUs) on 2026-02-04. The award was reported on a Form 4 filed 2026-02-06. The RSUs were granted at $0.00 per share (i.e., no immediate cash purchase), so there is no immediate dollar value realized on grant.

Key Details

• Transaction date: 2026-02-04; Form 4 filed: 2026-02-06 (filed within the normal two-business-day window).
• Transaction type/code: A — Award/Grant.
• Shares/units granted: 24,000 RSUs; reported acquisition price: $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote (F1): RSUs vest one year from the grant date. Underlying shares will not be delivered and may not be transferred or sold until the earlier of separation from service, death, disability, or a change in control.
• No 10b5‑1 plan, tax‑withholding sale, or other special arrangements were reported in the provided data.

Context
RSUs are a form of equity compensation that convert to company stock only after vesting; they are not an immediate open‑market purchase or sale and do not necessarily indicate the insider’s short‑term view of the stock. The eventual value to the recipient will depend on Syndax’s share price at vesting and any applicable tax or forfeiture conditions.